Antibody Drug Conjugate News and Research

RSS

Novel and fully automated technique can speed up detection of stroke

Human emotion system laboratory team at the University of Turku and Turku PET Centre, Finland, introduces a fully automated method for acute ischemic lesion segmentation on brain MRIs and shows how artificial intelligence can reduce the work load of radiologists.

30 Mar 2020

One in five childhood deaths in England and Wales still due to infection

A new study published in the journal Archives of Diseases of Childhood in March 2020 reveals that despite a drop to less than half, compared to 25 years ago, infection is still a cause of significant mortality among children. The most common cause of infection-related deaths in this age group are respiratory infections.

24 Mar 2020

Sleep problems as an infant may cause behavioural problems later on

Researchers from the University of Birmingham have found that infants that have sleep problems may have emotional and behavioral issues as they grow into toddlers. Their study titled, “Parent-reported early sleep problems and internalizing, externalizing, and dysregulation symptoms in toddlers”, was published in the latest issue of the BMJ Paediatrics Open.

10 Mar 2020

Researchers evaluate effectiveness of medication assisted therapy for opioid use disorder

Rebecca Sutter, Assistant Professor, School of Nursing, College of Health and Human Services, and Allison Evans Cuellar, Professor, Health Administration and Policy, CHHS, are implementing and evaluating the effectiveness of a Mobile Medication Assisted Therapy Program in the Prince William Health District that will expand capacity for opioid use disorder support and services.

9 Feb 2020

New antibody-drug conjugate shows promising activity in salivary gland tumors

The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors, according to data published in the Annals of Oncology.

7 Jan 2020

FDA approves new drug to treat adults with advanced urothelial or bladder cancer

The U.S. Food & Drug Administration granted accelerated approval to the drug enfortumab vedotin (EV) to treat adult patients with advanced urothelial or bladder cancer.

19 Dec 2019

New combination therapy can lead to durable responses in patients with multiple myeloma

An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies.

17 Dec 2019

One Nucleus reveals finalists of annual BioNewsRound Award

One Nucleus reveals the finalists of its annual BioNewsRound Award, recognizing life science companies that have announced exciting developments for patients and the sector. The finalists will present at Genesis 2019 where the winner will be announced.

29 Nov 2019

Lung inflammation in a case of a 16-year-old linked to vaping

The Centre for Disease Control and Prevention (CDC) has warned earlier last month about the possible risk of lung inflammation from the exposure to the fluid in e-cigarettes. Now a case of a 16-year-old boy was reported with life threatening lung inflammation leading to respiratory failure.

12 Nov 2019

Investigators use the power of computation to build better targeted drug therapy

Antibody drug conjugates (ADCs) -- cancer drugs that are designed to target and destroy cancerous tissue while leaving healthy cells intact -- represent a long sought-after advancement in cancer therapy.

8 Nov 2019

Femtogenix announces new data on ADCs containing reduced potency payloads in solid tumor models

Femtogenix Ltd, a UK biotechnology company developing the next generation of DNA-interactive Antibody Drug Conjugate payloads, today announced data demonstrating the potent efficacy and favorable toxicity profile of a reduced potency analogue from its Pyridinobenzodiazepine ADC payload platform in solid tumor models.

From Pheon Therapeutics 29 Oct 2019

Femtogenix announces efficacy, toxicity data of new DNA-binding ADC payload molecules

Femtogenix Ltd, a UK biotechnology company developing the next generation of DNA-interactive Antibody Drug Conjugate (ADC) payloads, today announced data verifying the favorable toxicity profile and potent efficacy of its Pyridinobenzodiazepine (PDD) ADC payload platform in tumor cell models.

14 Oct 2019

UK health secretary “seriously” considering mandating childhood vaccination

The UK is “looking very seriously” at making vaccinations compulsory for all children attending school in England, according to the health secretary Matt Hancock.

1 Oct 2019

Innovative technology could help treat cancer more selectively and effectively

Treating cancer more selectively and more effectively - this could be achieved with an innovative technology developed by teams of researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie and the Ludwig-Maximilians-Universität München.

9 Aug 2019

Innovative technology could treat cancer more selectively and effectively

9 Aug 2019

New chemoimmunotherapy regimen for aggressive form of lymphoma gets FDA approval

A cancer therapy based on the work of Ben Seon, PhD, at Roswell Park Comprehensive Cancer Center has been approved by the U.S. Food and Drug Administration for patients with an aggressive form of non-Hodgkin lymphoma.

24 Jun 2019

Persistent poverty endangers health in 20% of UK children

A recent study shows that one in five children in the UK have a higher risk of developing adolescent mental health disorders or physical illness because of persistent poverty. This alarming scenario comes from a new paper published in the Archives of Disease in Childhood.

13 Jun 2019

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.

10 Jun 2019

Antibody-drug conjugate effectively targets surface protein in childhood neuroblastomas

Physician-scientists in the Cancer Center at Children's Hospital of Philadelphia have developed a preclinical, potent therapy attached to an antibody that targets a surface protein expressed in most childhood neuroblastomas, effectively killing cancer cells.

14 Mar 2019

Porvair Sciences to improve the diagnosis and treatment of ovarian cancer

Porvair Sciences reports on its involvement in a new £2.6 million project led by Swansea University (UK) that aims to dramatically improve the diagnosis and treatment of ovarian cancer.

From Chromatrap® - Porvair Sciences Ltd 27 Feb 2019